Introduction
The UK’s advertising watchdog has stepped in against an online healthcare company over claims made in its marketing for at-home hormone tests. The Advertising Standards Authority (ASA) ruled that five advertisements from Voy were misleading because they suggested everyday issues such as tiredness and irritability could be strong signs of low testosterone. The company has agreed to pull the ads and not reuse them. The decision is part of a broader review of how men’s health products are advertised in Britain.
What Happened
The ASA upheld complaints against three posters and two paid Facebook advertisements promoting Voy’s at-home testosterone blood tests. According to the regulator, the ads connected common symptoms—including low energy, low sex drive, loss of motivation, and mood changes—to low testosterone in a way that overstated the evidence. One Facebook ad claimed that low testosterone affects one in four men over 30, a statement the ASA said Voy could not support with data.
Some of the posters had already drawn attention earlier this year after appearing on the London Underground, with slogans suggesting that men’s behavior is driven by hormones. Critics described the campaign as 'ragebait,' though Voy said at the time that it wanted to reduce stigma around men’s health conversations.
Voy confirmed it withdrew the advertisements while the investigation was ongoing and stated it would not run them again.
Why This Matters
The ruling highlights a tightening regulatory environment for companies that sell hormone tests and related treatments directly to consumers. The NHS notes that while testosterone levels naturally decline with age, that drop is unlikely to cause problems on its own, and symptoms such as erectile dysfunction or loss of libido are not always linked to hormone deficiency. Because many everyday factors can temporarily affect test results—such as the time of day, recent meals, illness, or poor sleep—the ASA warned that advertisers must not present nonspecific symptoms as reliable indicators of low testosterone without solid evidence.
This decision follows similar ASA rulings in August against two other online providers, BioID Health and Numan Digital Healthcare, and forms part of a wider investigation into advertising that targets men’s insecurities about ageing, libido, and sexual performance.
Key Takeaways
- The ASA banned five Voy advertisements for at-home testosterone tests.
- The ads were found misleading for linking everyday symptoms like fatigue and irritability to low testosterone without sufficient evidence.
- One claim suggested one in four men over 30 experiences low testosterone; the ASA said this was unsupported.
- Voy removed the ads during the investigation and said it would not reuse them.
- The ruling is part of a broader crackdown on men’s health advertising that plays on anxieties around hormones and ageing.
Conclusion
For consumers, the ASA’s decision is a reminder to approach at-home hormone test marketing with caution. Symptoms such as low mood, tiredness, or reduced sex drive can have many causes, and a single blood test is not always a clear-cut answer. Anyone concerned about their hormone levels should speak with a qualified healthcare professional rather than relying on advertising claims. Meanwhile, companies in the men’s health space can expect continued scrutiny from regulators as the ASA monitors whether promotional material stays accurate, evidence-based, and free from exaggeration.

Discussion
Join the conversation
Thoughtful reactions, questions, and follow-up ideas help shape the next story.